Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve zapping eases migraine pain in new study

NCT ID NCT07343427

Symptom relief Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a treatment called pulsed radiofrequency (PRF) on a nerve at the back of the head can help people with migraines. Researchers measured pain sensitivity and disability in 100 adults before and up to 3 months after the procedure. The goal is to see if this treatment can reduce migraine-related symptoms and improve daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older Diagnosis of episodic or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) Planned to undergo ultrasound-guided greater occipital nerve pulsed radiofrequency as part of routine clinical care Ability to complete self-reported questionnaires (CSI, ASC-12, MIDAS) Willingness and ability to provide written informed consent Exclusion Criteria: * Presence of other primary headache disorders (e.g., cluster headache, tension-type headache as the primary diagnosis) Secondary headache disorders, including headache attributed to structural, infectious, inflammatory, or vascular causes Prior greater occipital nerve pulsed radiofrequency treatment within the past 12 months History of cervical spine surgery, significant cervical trauma, or structural pathology that may interfere with the procedure Known coagulopathy or current use of anticoagulant therapy that cannot be safely interrupted Local infection at or near the planned injection site Severe uncontrolled psychiatric or neurological disorders that may impair study participation or questionnaire reliability Pregnancy or breastfeeding Inability to comply with follow-up visits or study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central sensitization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central sensitization Migraine

Contacts and locations

Locations

  • Ankara Bilkent City Hospital

    Ankara, Ankara, 06810, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.